Keyword: Johnson & Johnson
A new report outlines 12 drugs launching this year that analysts expect to reel in big sales, with top drugmakers Roche, J&J and Gilead represented.
Sun Pharma’s $80 million psoriasis licensing deal just paid off. But now, its new drug Ilumya will go up against established player J&J.
Former Eli Lilly CFO Derica Rice becomes the second top Big Pharma ex to take the reins at a major pharmacy benefit manager.
Despite uncertainty heading into 2017, most drug stocks escaped the stagnation of 2016—some far more than others.
Here's some other vaccine news of note for the week.
Amid a particularly severe flu season, FDA chief Scott Gottlieb said the "holy grail" of vaccines—a shot that fights any strain of virus—is years off.
Johnson & Johnson is trumpeting more Invokana outcomes data to support its approval to reduce cardiovascular risks.
When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.
With a new study in patients with peripheral artery disease, Johnson & Johnson has once again bolstered its case for another Xarelto approval.
A judge has ordered 1,200 Xarelto liability cases against J&J and Bayer to be prepared for trial in courts around the country.